Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.
Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group. Grønberg BH, et al. Among authors: sundstrom s. Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23. Acta Oncol. 2016. PMID: 26494411 Clinical Trial.
Chemotherapy and quality of life in NSCLC PS 2 patients.
Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø U, Von Plessen C, Bremnes RM; Norwegian Lung Cancer Study Group. Helbekkmo N, et al. Acta Oncol. 2009;48(7):1019-25. doi: 10.1080/02841860902795240. Acta Oncol. 2009. PMID: 19274496 Clinical Trial.
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.
Strøm HH, Bremnes RM, Sundstrøm SH, Helbekkmo N, Fløtten O, Aasebø U. Strøm HH, et al. Among authors: sundstrom sh. Br J Cancer. 2013 Sep 17;109(6):1467-75. doi: 10.1038/bjc.2013.466. Epub 2013 Aug 20. Br J Cancer. 2013. PMID: 23963145 Free PMC article. Clinical Trial.
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Sundstrøm S, et al. J Clin Oncol. 2002 Dec 15;20(24):4665-72. doi: 10.1200/JCO.2002.12.111. J Clin Oncol. 2002. PMID: 12488411 Clinical Trial.
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S. Sundstrøm S, et al. J Clin Oncol. 2004 Mar 1;22(5):801-10. doi: 10.1200/JCO.2004.06.123. J Clin Oncol. 2004. PMID: 14990635 Clinical Trial.
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S; Norwegian Lung Cancer Study Group. Sundstrøm S, et al. Lung Cancer. 2005 May;48(2):251-61. doi: 10.1016/j.lungcan.2004.10.016. Epub 2004 Dec 15. Lung Cancer. 2005. PMID: 15829326 Clinical Trial.
126 results